GLPwatch

Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations.

Proc Natl Acad Sci U S A · 2013

Last updated 2026-05-28

Researchers studied how different signals are triggered when certain drugs bind to the glucagon-like peptide-1 receptor, which is used to treat type 2 diabetes. They found that specific parts of the receptor, called polar transmembrane residues, play a key role in shaping how the receptor responds to different drugs, including the natural hormones glucagon-like peptide-1 and oxyntomodulin, as well as the drug exendin-4.

AI summary of the abstract below.

JournalProc Natl Acad Sci U S A, 2013
Citations207
Relative citation ratio5.98
NIH percentile94
Molecules

Abstract

Recently, the concept of ligand-directed signaling--the ability of different ligands of an individual receptor to promote distinct patterns of cellular response--has gained much traction in the field of drug discovery, with the potential to sculpt biological response to favor therapeutically beneficial signaling pathways over those leading to harmful effects. However, there is limited understanding of the mechanistic basis underlying biased signaling. The glucagon-like peptide-1 receptor is a major target for treatment of type-2 diabetes and is subject to ligand-directed signaling. Here, we demonstrate the importance of polar transmembrane residues conserved within family B G protein-coupled receptors, not only for protein folding and expression, but also in controlling activation transition, ligand-biased, and pathway-biased signaling. Distinct clusters of polar residues were important for receptor activation and signal preference, globally changing the profile of receptor response to distinct peptide ligands, including endogenous ligands glucagon-like peptide-1, oxyntomodulin, and the clinically used mimetic exendin-4.

Verbatim abstract via PubMed 23479653 ↗